An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 in Patients With Advanced Hematological Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Jul 2018
At a glance
- Drugs BAY 1251152 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 20 Jul 2018 Planned End Date changed from 9 Jul 2018 to 6 Aug 2018.
- 20 Jul 2018 Planned primary completion date changed from 9 Jul 2018 to 6 Aug 2018.
- 20 Jul 2018 Status changed from recruiting to active, no longer recruiting.